H.R. 10094, Drug Price Control via Federal Funding Leverage. Quorum's AI analysis reads it as a net benefit — and names who gains.

What it does

This bill requires any company or researcher receiving federal funding for biomedical research to agree that the resulting drug, vaccine, device, or therapy will be priced reasonably—specifically, no higher than the median price charged in Canada and six other wealthy nations. The Secretary of HHS sets the pricing rules, can waive them if in the public interest, and requires companies to report clinical trial costs, federal subsidies, and annual revenues by county. The goal is to ensure taxpayers don't subsidize research only to pay inflated prices for the resulting products.

The analysis names patients and consumers (lower drug prices) — and 2 more groups — among the beneficiaries.

The trade-off

Companies may decline federal funding to avoid pricing obligations, potentially fragmenting publicly-funded research into private-only tracks and reducing transparency of taxpayer-supported innovation.

Transparency scores 72%, with a medium warning level and no provisions unrelated to the bill's subject.

Who is behind it

Filed by Valerie Hoyle. Cosponsored by Chuy García, Eleanor Norton, Gregorio Casar and Jan Schakowsky.